Alexandra Giatromanolaki
Overview
Explore the profile of Alexandra Giatromanolaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
250
Citations
8762
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koukourakis M, Giatromanolaki A, Zois C, Kalamida D, Pouliliou S, Karagounis I, et al.
Sci Rep
. 2025 Feb;
15(1):4069.
PMID: 39900942
No abstract available.
2.
Katsaros I, Sotiropoulou M, Vailas M, Papachristou F, Papakyriakopoulou P, Grigoriou M, et al.
Nutrients
. 2025 Jan;
16(24.
PMID: 39770904
Non-alcoholic fatty liver disease (NAFLD) is a major metabolic disorder with no established pharmacotherapy. Quercetin, a polyphenolic flavonoid, demonstrates potential hepatoprotective effects but has limited bioavailability. This study evaluates the...
3.
Iakovakis T, Drakopanagiotakis F, Tirikidou E, Giatromanolaki A, Kouroupi M, Georgakopoulou V, et al.
Cureus
. 2024 Dec;
16(11):e74450.
PMID: 39726495
Recurrent respiratory papillomatosis (RRP) is a challenging disease to manage, due to its highly recurring nature and the lack of a definitive treatment. It is characterized by the presence of...
4.
Kontomanolis E, Koutras A, Mitrakas A, Trypsianis G, Nikolettos K, Tsikouras P, et al.
Anticancer Res
. 2024 Dec;
44(12):5525-5530.
PMID: 39626943
Background/aim: The prognostic role of tissue PD-L1 expression in endometrial cancer (EC) remains controversial. Moreover, its value in guiding anti-PD1/PD-L1 immunotherapy is questionable. The eventual role of soluble PD-L1 (sPD-L1),...
5.
Xanthopoulou E, Lamprou I, Mitrakas A, Michos G, Zois C, Giatromanolaki A, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409895
Background/objectives: Immune checkpoint inhibitors have an established role in non-small cell lung cancer (NSCLC) therapy. The loss of HLA-class-I expression allows cancer cell evasion from immune surveillance, disease progression, and...
6.
Tsochantaridis I, Brisimis D, Tsifintaris M, Anastasiadou A, Lazos E, Ermogenous A, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408636
Aldehyde dehydrogenases (ALDHs) constitute a diverse superfamily of NAD(P)-dependent enzymes pivotal in oxidizing endogenous and exogenous aldehydes to carboxylic acids. Beyond metabolic roles, ALDHs participate in essential biological processes, including...
7.
Diamantidis D, Tsakaldimis G, Georgellis C, Lailisidis S, Panagiotopoulos N, Kafalis C, et al.
Prz Menopauzalny
. 2024 Oct;
23(2):109-112.
PMID: 39391526
The diagnostic complexities posed by lesions within the urinary bladder underscore the need for personalised management approaches. Endocervicosis, a rare condition stemming from Müllerian tissue, is characterised by the benign...
8.
Gavriilidis E, Divolis G, Natsi A, Kafalis N, Kogias D, Antoniadou C, et al.
Front Immunol
. 2024 Sep;
15:1447608.
PMID: 39346917
Introduction: Crohn's disease (CD) is characterized by chronic inflammation and intestinal fibrosis leading to lifelong complications. However, the disease pathogenesis remains elusive, and the therapeutic options are limited. Here, we...
9.
Giatromanolaki A, Kavazis C, Gkegka A, Kouroupi M, Tsaroucha A, Pitiakoudis M, et al.
Immunobiology
. 2024 Jun;
228(6):152756.
PMID: 38860277
Introduction: Mismatch repair deficiency, immunological fertility, and PD-L1 expression status are key histopathological and molecular features defining tumor responsiveness to immunotherapy and, eventually, prognosis. These were investigated in a series...
10.
Kontomanolis E, Symeonidis P, Nikolettos K, Perros P, Rody A, Tsikouras P, et al.
In Vivo
. 2024 Apr;
38(3):1260-1265.
PMID: 38688602
Background/aim: Endometrial cancer (EC) is the predominant malignancy among gynecologic cancers and ranks fourth among all types of cancer. Recently, researchers have focused on the development of new prognostic biomarkers....